Pedro P. Costa
Columbia University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pedro P. Costa.
Human Genetics | 1989
Katsuji Yoshioka; Hirokazu Furuya; Hiroyuki Sasaki; Maria João Saraiva; Pedro P. Costa; Yoshiyuki Sakaki
SummaryFamilial amyloidotic polyneuropathy (FAP) is an autosomal dominant genetic disease characterized by systemic accumulation of amyloid fibrils. A major component of FAP anyloid has been identified as variant transthyretin (TTR, also called prealbumin). In particular, a variant with the substitution 30Val→Met has been commonly found in FAP of various ethnic groups. To understand the origin and spread of the Val→Met mutation, we analyzed DNA polymorphisms associated with the TTR gene in six Japanese FAP families and several Portuguese FAP patients. Three distinct haplotypes associated with the Val→Met mutation were identified in Japanese FAP families, one of which was also found in Portuguese patients. On the other hand, it was found that the Val→Met mutation can be explained by a C-T transition at the CpG dinucleotide sequence of a mutation hot spot. Thus, our findings indicate that the Val→Met mutation has probably recurred in the human population, to generate FAP families of independent origin.
Neurology | 1986
Maria João Saraiva; Pedro P. Costa; DeWitt S. Goodman
Two studies were conducted to explore questions concerning the expression of a mutant transthyretin (TTR) gene, found in Portuguese patients with familial amyloidotic polyneuropathy (FAP). In a kindred with typical onset of the disease, complete agreement between genotype and phenotype was seen for all carriers of the variant TTR with a methionine-for-valine substitution at position 30 (TTR[Met30]). In another study involving a FAP kindred with a late onset of clinical disease, TTR(Met30) was found in plasma in asymptomatic persons with ages above the usual age of onset of the disease. No evidence was obtained for the existence of a different mutation in TTR or for repression of the expression of the mutant TTR gene in this kindred. The factors responsible for the delay in the development of clinical manifestations in late-onset patients are not known and warrant further study.
The American Journal of Medicine | 1992
Ida Ranløv; Isabel L. Alves; Poul Jørgen Ranløv; Gunnar Husby; Pedro P. Costa; Maria João Saraiva
PURPOSE In familial amyloid cardiomyopathy of Danish origin, the amyloid microfibrils contain a mutant transthyretin (TTR) with a methionine-for-leucine substitution at the molecular position 111. We studied the possible occurrence of this variant TTR-Met111 in serum from afflicted as well as nonafflicted family members and their offspring, in order to define its possible role as predictor of the disease and to describe its mode of inheritance. PATIENTS AND METHODS Stored, frozen serum samples obtained from 1959 through 1960 from 36 of 40 living members of the kindred were analyzed. The method employed to detect the abnormal TTR was based on the electrophoretic separation of fragments produced by cyanogen bromide cleavage at the two methionine sites. RESULTS All sera from family members with amyloid cardiomyopathy contained the variant transthyretin TTR-Met111 as did sera from half of their offspring. In contrast, nonafflicted family members and their offspring were seronegative for TTR-Met111. Three cousins from the second generation died between 1980 and 1986 of amyloid cardiomyopathy. The presence of variant TTR-Met111 preceded their deaths by 20 to 26 years. CONCLUSIONS The occurrence in serum of the mutant transthyretin TTR-Met111 is linked to the occurrence of amyloid cardiomyopathy in patients and their offspring, while unafflicted branches of the family are negative for the variant protein. That the occurrence in serum of TTR-Met111 precedes the onset of clinical amyloid cardiomyopathy by several decades makes the variant TTR a marker for the disease. The distribution of afflicted family members and seropositivity for the variant TTR shows an autosomal dominant mode of inheritance. CLINICAL SIGNIFICANCE The results make possible early detection of potential patients and provide tools for genetic counseling. Cardiac transplantation may provide a new therapeutic option.
Annals of the New York Academy of Sciences | 2005
Rita de Sousa; Nahed Ismail; Sónia Dória‐Nóbrega; Pedro P. Costa; Tiago Abreu; Ana França; Mário Amaro; Paula Proença; Paula Brito; José Poças; Teresa Ramos; Graça Cristina; Graça Pombo; Liliana Vitorino; Jorge Torgal; Fátima Bacellar; David H. Walker
Abstract: In Portugal, Mediterranean spotted fever (MSF) is caused by R. conorii Malish and Israeli spotted fever (ISF) strains. It has been suggested that the ISF strain isolated from patients with MSF causes different clinical manifestations compared to those caused by Malish strain, namely the absence of eschar and greater severity. The aim of this study was to analyze the presence or absence of eschar and of fatality in Portuguese patients infected with either Malish or ISF strain. Of 94 patients with a clinical diagnosis of MSF between 1994 to 2004, 47 were infected with Malish strain and 47 with ISF strain. Eschars were reported in 20 patients (49%) infected with Malish strain, and in 17 (39%) with ISF strain. The presence of eschar is not statistically associated to a greater extent with either R. conorii strain (P= 0.346). A total of 22 patients died, 9 infected with Malish strain and 13 infected with ISF strain, and no statistically significant difference was found (P= 0.330). This study showed that the concepts of absence of the eschar and greater severity in Israeli spotted fever infection should be revised.
Human Genetics | 1990
Maria Rosário Almeida; Isabel L. Alves; Yoshiuki Sakaki; Pedro P. Costa; Maria João Saraiva
SummaryTransthyretin methionine 30 (TTR Met 30), which is associated with familial amyloidotic polyneuropathy, originates in a single base substitution (A for G) in the second exon of the TTR gene. This autosomal dominant disease can be diagnosed by RFLP analysis of NsiI-digested DNA. The amplification of DNA by PCR improves the diagnosis method, making it suitable for prenatal diagnosis. Using PCR-amplified DNA, prenatal diagnosis of two at-risk fetuses was performed. Control Met 30 and normal DNA (either genomic or produced by site directed mutagenesis) were processed in parallel. The diagnosis was made by hybridization with allele-specific oligonucleotide probes, and later confirmed by screening of the mutant protein in the amniotic fluid and, when possible, in the sera from the newborns. TTR Met 30 was detected in the amniotic fluid of a positive fetus whose father was the carrier of the mutation. This indicates that the mutant protein is expressed very early in development.
Human Genetics | 1995
Maria Rosário Almeida; N. Aoyama-Oishi; Yoshiyuki Sakaki; Gösta Holmgren; Drugge Ulf; Alessandra Ferlini; Fabrizio Salvi; Miguel Munar-Qués; Merrill D. Benson; Martha Skinner; Pedro P. Costa; Maria João Saraiva
The most frequent transthyretin (TTR) variant associated with hereditary amyloidosis is TTR Met 30, which has its major focus in Portugal, although it also occurs in many other countries. The distribution of the mutation and its occurrence in a CpG dinucleotide lead us to question the origin of the mutation and the possibility of its having originated in Portugal. In order to investigate these questions, we studied the distribution of haplotypes associated with the Met 30 mutation in families from different European countries. All the analysed Portuguese families presented the same haplotype associated with the Met 30 mutation (haplotype I). The same was found for the Swedish and Spanish families studied. However, a distinct haplotype (haplotype III) was found in three families, one Italian, one English and one Turkish. These results suggest that, although the Portuguese Met 30 carriers might have one founder, the mutation probably recurred in populations in Europe in a similar manner to that reported in Japan. In this study, we have also analysed the haplotypes associated with other TTR variants frequent in the Portuguese population.
Biochemical and Biophysical Research Communications | 1989
Hirokazu Furuya; Masamitsu Nakazato; Maria João Saraiva; Pedro P. Costa; Hiroyuki Sasaki; Hisayuki Matsuo; Ikuo Goto; Yoshiyuki Sakaki
A variant of human transthyretin(TTR, prealbumin) with methionine for valine substitution at position 30 is a major component of amyloid fibrils found in patients of familial amyloidotic polyneuropathy(FAP) type I, an autosomal dominant genetic disease. But the molecular nature of the variant TTR has been obscure, because most of plasma TTR from FAP patients is a mixture of variant and wild type TTR and no pure preparation of the variant has been available. For this reason, we constructed a system in which the variant type TTR was efficiently synthesized. In this system, the recombinant variant TTR was first synthesized as a fusion protein with E. coli outer membrane protein A (ompA) signal peptide, processed to eliminate the signal peptide and finally secreted to the culture medium. The final concentration of the recombinant variant TTR in the medium was about 5 mg/l. SDS polyacrylamide gel electrophoresis and gel filtration analysis suggested that the recombinant variant TTR can form tetramer as seen for native one. Purification of the protein was accomplished by only two steps of chromatography.
Amyloid | 1997
Miguel Munar-Qués; Pedro P. Costa; Maria João Saraiva; Carlos Viader-Farré; Catalina Munar-Bernat; Carmen Cifuentes-Luna; José Francisco Forteza-albertí
We analyzed data from 78 Majorcan patients with familial amyloidotic polyneuropathy (FAP): 57 confirmed and 21 non-confirmed. Diagnosis was established in the first group by histopathological study or detection of the biochemical marker in serum, and in the second was sup-ported by clinical information and family history.Eighteen confirmed patients were isolated cases and 39 had a family history of FAP. Age of onset was 46. 7 years; later in males; predominance of males (72%) and late on-set cases (65%). The TTR variant was Met 30 associated with haplotype I. Initial sensorimotor syndrome was present only in 55% of patients. Multiple progressive handicaps appeared. Duration averaged 10.5 years and was longer in males. Prevalence rate was 3.3 patients per 100,000 and asymptomatic carriers were 83. Twelve patients underwent liver transplantation.Since 1989, the number of FAP families, patients, prevalence, isolated cases and municipalities with affected families was increased. One founder hypothesis is supp...
Biochimica et Biophysica Acta | 1991
Maria do Rosário Almeda; Klaus Altland; Silke Rauh; MaryAnn Gawinowicz; Paul Moreira; Pedro P. Costa; Maria João Saraiva
A basic transthyretin (TTR) variant, apparently non-pathogenic, has been reported in a German family. Protein analysis of this TTR variant revealed the substitution of arginine for proline at position 102 of the TTR polypeptide chain. This result was confirmed by DNA analysis of PCR amplified DNA.
Human Genetics | 1988
Maria João Saraiva; Pedro P. Costa; Maria Rosário Almeida; Angelika Banzhoff; Klaus Altland; Alessandra Ferlini; Guido Rubboli; Rosaria Plasmati; C. A. Tassinari; Giovanni Romeo; Fabrizio Salvi
SummaryAs part of an epidemiological study that aims to characterize chemically the mutation(s) in transthyretin (TTR) related to familial amyloidotic polyneuropathy (FAP) of different ethnic origins, studies were carried out on TTR from two FAP kindreds of Italian origin. Two different criteria were employed in the characterization of TTR from these kindreds: (1) immunoblotting of cyanogen bromide fragments for screening of TTR(Met30) and (2) isoelectric focusing. TTR(Met30) was not detected but other substitutions were demonstrated using isoelectric focusing techniques. One of the variants found is a basic TTR variant. The substitutions occurring in the variant TTRs of these two kindreds are not known and are presently under study.